Phase 3 Readout~month

Phase 3 Topline: A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effica

Indication
Cutaneous T Cell Lymphoma; Mycosis Fungoides; CTCL/ Mycosis Fungoides

Other upcoming events for SNGX

Patent ExpiryPatent/Exclusivity Expiry: VALCHLOR

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Confirmatory Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Effica — SNGX Phase 3 Readout | BioSniper